2023 World Conference on Lung Cancer (Posters)-P1.27. Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung

P1.27. Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung - PDF(Abstract)

Back to course

Pdf Summary

This document describes the results of a phase II clinical trial investigating the use of dual anti-CTLA-4 and anti-PD-1 blockade in bronchioloalveolar carcinoma (BAC) of the lung. BAC is a rare form of lung cancer that typically has a poor response to chemotherapy. The trial, called SWOG S1609 DART, aimed to evaluate the efficacy of immunotherapy in BAC.<br /><br />The trial included eight patients with BAC who were treated with ipilimumab and nivolumab. The primary endpoint of the study was the objective response rate (ORR), and secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity.<br /><br />The results showed that two patients achieved partial responses (ORR of 25%), with one patient experiencing ongoing regression after almost 46 months of treatment. Two additional patients had stable disease with ongoing PFS of over 1000 days. The overall clinical benefit rate (CBR), defined as no progression at 6 months, was 63%.<br /><br />The median PFS was 16 months, and the median OS was 32.2 months. The most common adverse events reported were fatigue and skin rash, and grade 3-4 adverse events occurred in 50% of patients.<br /><br />Overall, the combination of ipilimumab and nivolumab showed promising results in BAC, with durable responses seen. Further studies are needed to determine response and resistance markers, and expanded prospective studies in BAC are warranted.

Asset Subtitle

Young Kwang Chae

Meta Tag

Speaker Young Kwang Chae

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

phase II clinical trial

bronchioloalveolar carcinoma

immunotherapy

objective response rate

progression-free survival

overall survival

adverse events

ipilimumab

nivolumab

durable responses